Published in Gene Therapy Weekly, September 25th, 2008
The net proceeds of the private placement will be used to advance the Company's clinical development programs, including lead product JX-594, which is currently being evaluated in a randomized Phase II clinical trial for liver cancer. This is one of three clinical trials currently under way, which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.